進階篩選

Technical category
技術研發單位
    • 變種冠狀病毒蛋白晶片:疫情與後疫情時代之應用

      Precision Health Ecosystem FutureTech 變種冠狀病毒蛋白晶片:疫情與後疫情時代之應用

      Due to the recent outbreak of COVID-19ongoing mutants, we developed a coronavirus variant protein microarray that includes all the current spike mutationsthe wild-type viral antigensapplied in detecting immune responsesdrug specificities. We filed the patientspublished our findings in the Analytical Chemistry. Besides massive production of the coronavirus protein microarray, we also collaborated with a scanner company, developed artificial intelligence software,collaborated with suppliers. We are welcome any sort of collaboration.
    • 器官晶片-三維細胞培養與藥物測試篩選的陣列平台

      Precision Health Ecosystem FutureTech 器官晶片-三維細胞培養與藥物測試篩選的陣列平台

      Lung-on-minilab is designed as a tool for personalized healthcarewill contribute in precision medicine. Here, the tumor microenvironment was reconstituted using liquid dielectrophoresisarranged as lung tissue. The size of pattern can be customized as stages of cancer. Additionally, this chip was equipped a gradient microfluidic channel which enabled testing combination of medications. This is the first device where chemotherapyimmunotherapy medications can be tested together. This will improve the screening timeserve as an alternative for patients in therapeutic try.
    • 5D智慧城市─SmartES平台

      AI & IOT Application FutureTech 5D智慧城市─SmartES平台

      NCREE has originally developed 5D digital space—on the basis of 3D city modelsconnections of different kinds of sensors around the world— is an online to offline virtual space with a combination of rising 5G technology advantages. Collectingreorganizing various 3D cartographic data with Building Information Modeling (BIM), satellite imagery, UAV 3D modeling, LiDar point cloud data, etc., can increase the diversity of the buildinglandscape. 5D+5G smart city platform would accelerate the 5D smart city to become the digital twin of a real city.
    • 生物製造之癌症晶片應用於患者特異性用藥預測平台

      FutureTech 生物製造之癌症晶片應用於患者特異性用藥預測平台

      The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.